Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI

Journal of Neural Transmission

Volumn 122, Issue 5, 2015, Pages 721-729

  Sigurdsson, H P ^a   Hefner, G ^a   Ben Omar, N ^b   Kostlbacher A ^b   Wenzel Seifert, K ^b   Hiemke, C ^a   Haen, E ^b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Late life depression; Pharmacokinetics; Therapeutic drug monitoring; Venlafaxine

Indexed keywords

DESVENLAFAXINE; VENLAFAXINE; ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; GROUPS BY AGE; HUMAN; LATE LIFE DEPRESSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; STEADY STATE; TREATMENT OUTCOME; ADOLESCENT; AGING; BLOOD; DATA MINING; DEPRESSIVE DISORDER; DRUG DATABASE; DRUG EFFECTS; GERMANY; MIDDLE AGED; ONSET AGE; SEXUAL DEVELOPMENT; UNIVERSITY HOSPITAL; YOUNG ADULT;

ACADEMIC MEDICAL CENTERS; ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGING; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DATA MINING; DATABASES, PHARMACEUTICAL; DEPRESSIVE DISORDER; DESVENLAFAXINE SUCCINATE; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; VENLAFAXINE HYDROCHLORIDE; YOUNG ADULT;

EID: 84928656918     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-014-1317-9     Document Type: Article

References (35)

1. Alexopoulos GS (2005) Depression in the elderly. Lancet 365:1961–1970
2. Allard P, Gram L, Timdahl K, Behnke K, Hanson M, Sogaard J (2004) Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psych 19:1123–1130
3. Amore M, Ricci M, Zanardi R, Perez J, Ferrari G (1997) Long-term treatment of geropsychiatric depressed patients with venlafaxine. J Affect Disorders 46:293–296
4. Blazer DG (2003) Depression in late life: review and commentary. J Gerontol A Biol Sci Med Sci 58A(3):249–265
5. Büchtemann D, Luppa M, Bramesfeld A, Riedel-Heller S (2012) Incidence of late-life depression: a systematic review. J Affect Disorders 142:172–179
6. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J (2011) Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 343:1–15
7. Dierick M (1996) An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients. Ann Clin Psychiatry 8(3):169–178
8. Fogelman SM, Schmider J, venkatakrishnan K, von Moltke LL, Harmatz JS, Shader RI, Greenblatt DJ (1999) O- and N-demethylation of venlafaxine in vitro by human liver mucrosomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacol 20(5):480–490
9. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF (2004) Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol 44:499–523
10. Gastó C, Navarro V, Marcos T, Portella MJ, Torra M, Rodamilans M (2003) Single-blind comparison of venlafaxine and nortriptyline in elderly major depression. J Clin Psychopharm 23(1):21–26
11. Harvey AT, Rudolph RL, Preskorn SH (2000) Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiat 57:503–509
12. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, Zernig G (2011) AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44(6):195–235
13. Holliday SM, Benfield P (1995) Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 49(2):280–294
14. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, Brockmöller J (2001) CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiat Scand 104(3):173–192
15. Klamerus KJ, Parker VD, Rudolph RL, Derivan AT, Chiang ST (1996) Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy 16(5):915–923
16. Kloiber S, Ising M, Reppermund S, Horstmann S, Dose T, Majer M, Lucae S (2007) Overweight and obesity affect treatment response in major depression. Biol psychiat 62:321–326
17. Mallet L, Spinewine A, Huang A (2007) The challenge of managing drug interactions in elderly people. Lancet 370:185–191
18. Marazziti D, Baroni S, Picchetti M, Piccinni A, Carlini M, Vatteroni E, Dell´Osso L (2013) Pharmacokinetics and pharmacodynamics of psychotropic drugs: effect of sex. CNS Spectr 18:1–10
19. McAlpine DE, Biernacka JM, Mrazek DA, O´Kane DJ, Stevens SR, Langman LJ, Moyer TP (2011) Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit 33(1):14–20
20. Nagler EV, Webster AC, Vanholder R, Zoccali C (2012) Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transpl 27:3736–3745
21. Pfizer (2013) Retrieved 15 May 2013 from http://www.fachinfo.de/data/fi/jsearch?wirkstoff
22. Pirmohamed M, Park BK (2001) Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 22(6):298–305
23. Reis M, Lundmark J, Björk H, Bengtsson F (2002) Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit 24:533–545
24. Reis M, Aamo T, Spigset O, Ahlner J (2009) Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit 31(1):42–56
25. Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ (2004) Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Pharmacol 24(1):70–78
26. Schmitt G, Herbold M, Peters F (2003). Methodenvalidierung im forensisch-toxikologischen labor. In: Herbold M (ed) Arvecon, Germany
27. Shams MEE, Arneth B, Hiemke C, Dragicevic A, Müller MJ, Kaiser R, Härtter S (2006) CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 331:493–502
28. Singh A, Antognini JF (2010) Perioperative pharmacology in elderly patients. Curr Opin Anesthesio 23:449–454
29. Thase ME, Entsuah AR, Rudolph RL (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Brit J Psychiat 178:234–241
30. Turnheim K (2003) When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 38:843–853
31. Unterecker S, Deckert J, Pfuhlmann B (2011) No influence of body weight on serum levels of antidepressants. Ther Drug Monit 33(6):730–734
32. Unterecker S, Hiemke C, Greiner C, Haen E, Jabs B, Deckert J, Pfuhlmann B (2012) The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions. Pharmacopsychiatry 45(6):229–235
33. Unterecker S, Riederer P, Proft F, Maloney J, Deckert J, Pfuhlmann B (2013) Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions. J Neural Transm 120(8):1237–1246
34. Waade RB, Molden E, Refsum H, Hermann M (2012) Serum concentrations of antidepressants in the elderly. Ther Drug Monit 34(1):25–29
35. WHO (2004) International statistical classification of diseases and health related problems. World Health Organization, Geneva